Creatine Kinase MB

Short Description:


Product Detail

Product Tags

Key Product Characteristics

Kit Name : Joinstar Creatine Kinase MB Isoenzyme Detection Kit

Method: Fluorescence dry quantitative immunoassay

Assay measuring range: 1.0 ng/mL ~ 80.0 ng/mL

Incubation time: 15min

Sample: Human plasma specimens (EDTA anticoagulant),whole blood specimen (EDTA anticoagulant) , and serum

Reference range: <5.0 ng/mL

Storage and Stability: 

Detection Buffer is stable for 12 months at 2°C ~8°C. 

Sealed Test Device is stable for 12 months at 4°C30°C.

Introduction

Creatine Kinase MB (CK-MB) is the isoenzyme of creatine kinase, which is an enzyme system widely existing in human striated muscle. When striated muscle such as cardiac muscle damaged, CK-MB will be released into the blood.
It is detectable within 3–8 h of acute myocardial infarction (AMI), peaks within 8–24 h and can be present for up to 3-4 days.
It has been proposed as a useful biomarker of myocardial infarction(MI)and combined CK-MB with cTnI would have better guiding significance.

Consensus & Guidelines

《Third Universal Definition of Myocardial Infarction(2012)》
Myocardial injury is detected when blood levels of sensitive and specific biomarkers such as cTn or the MB fraction of creatine kinase (CK-MB) are increased. If a cTn assay is not available, the best alternative is CK-MB (measured by mass assay).

Clinical Applications

Early Diagnosis of AMI
CK-MB can be used for early diagnosis and risk stratification of AMI, it is detectable within 3–8 h after the occurence of AMI.
Coronary artery bypass grafting (CABG) prognosis with Non ST segment elevation(NSTE) myocardial infarction acute coronary syndromes(ACS)  
CK-MB elevations after CABG are independently associated with increased risk of mortality in patients with NSTE ACS. 
Percutaneous coronary intervention (PCI) prognosis
The value of post-procedural cardiac biomarkers such as CK-MB increased following PCI, the level of CK-MB was associated with impaired outcome.


  • Previous:
  • Next:


  • Previous:
  • Next:

  • Leave Your Message